ARK Genomic Revolution ETF vs Crocs, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $44.27, while Crocs, Inc. trades at $129.38 (market cap $6.31B). The key difference: ARK Genomic Revolution ETF is trading nearer its 52-week high, Crocs, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | CROX | |
|---|---|---|
Sector | Sector/Thematic | Consumer Staples |
52-Week High | $44.55 | $141.19 |
52-Week Low | $24.02 | $73.39 |
Market Cap | — | $6.31B |
Enterprise Value | — | $7.83B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Crocs (CROX) trades at $138.19, up 1.15% today, near its 52-week high. The stock shows bullish technical signals with strong earnings beats in recent quarters, including Q2 2026 EPS of $4.55 versus $4.35 expected. Revenue trends are stable around $4B annually, though 2025 net income was negative due to high taxes. Analysts maintain a buy-heavy consensus with a $140.43 price target.
Outlook is positive with robust profitability margins and valuation support, but risks include tax scrutiny from recent Malta office news and HEYDUDE brand weakness. The stock offers growth potential if execution improves, yet investors face volatility from guidance misses and competitive pressures.
Trailing returns across standard periods
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Crocs Inc is engaged in the design, development, marketing, distribution, and sale of casual lifestyle footwear accessories for men, women, and children. The reportable geographic segments of the company include Americas, Asia pacific, and EMEA.
Read more on CROX →